75. Mortality following hospitalization for acute coronary syndrome among HIV+ and HIV- patients
Session: Oral Abstract Session: HIV: Treatment, Complications, and Outcomes
Thursday, October 3, 2013: 8:45 AM
Room: The Moscone Center: 250-262
Background: HIV+ patients are at higher risk for cardiovascular disease (CVD). However, few studies have examined mortality following acute coronary syndrome (ACS).

Methods: We identified all adult HIV+ (n=226) and HIV- (n=86,321) Kaiser Permanente Northern California members with a first known admission for ACS, defined as ST elevation myocardial infarction (STEMI), non-ST elevation MI (NSTEMI), or unstable angina, between 1996-2010. Deaths were ascertained from hospital records, California death certificates, and Social Security Administration vital status files. 1- and 3-year all-cause mortality by HIV status was assessed by Kaplan-Meier. Adjusted hazard ratios (HR) for death by HIV status were obtained from Cox models adjusting for baseline age, sex, race, diagnosis year, admitting diagnosis, ever smoking status, and LDL, HDL, and TG levels. Finally, adjusted HRs were obtained for HIV+ patients stratified by CD4 and antiretroviral therapy (ART) class compared with HIV- patients.

Results: HIV+ patients were younger (54.6 vs. 67.4 years), more likely male (94.4% vs. 62.5%), and smoked more (71.5% vs. 55.3%) than HIV- patients. The admitting diagnosis for HIV+ vs. HIV- patients was more often STEMI (37.0% vs. 26.8%), and less often unstable angina (28.1% vs. 39.1%). Unadjusted survival after the ACS hospitalization was similar for HIV+ compared with HIV- patients at 1 year (92.4% vs. 90.2%; P=0.26) and 3 years (83.4% vs. 81.4%; P=0.43). However, being HIV+ was associated with higher adjusted HRs for death at 1 year (HR=2.2; 95% CI=1.3-3.5) and 3 years (HR=2.5; 95% CI=1.8-3.5). At 3 years, HIV+ patients with CD4≥500 cells/μL had similar mortality compared with HIV- patients with an HR of 0.7 (95% CI=0.2-2.1), while mortality was elevated for HIV+ patients with CD4 201-499 and CD4<200, with HRs of 2.5 (95% CI=1.6-4.0) and 5.6 (95% CI=3.2-9.7), respectively. HRs were similar for HIV+ patients compared with HIV- patients regardless of ART class.

Conclusion: Within a large, community-based sample of adults hospitalized for ACS, HIV patients were at greater risk of all-cause mortality, although no difference in mortality was observed at 3 years for HIV+ patients with high CD4+ cell counts. Future studies should investigate other outcomes, including ACS recurrence and CVD-specific mortality.

Michael Silverberg, PhD, MPH1, Leo Hurley, MPH1, Amit Prasad, MD2, Jonathan Zaroff, MD2, Daniel Klein, MD3, Michael Horberg, MD, MAS, FIDSA4, Alan Go, MD1 and Joan Lo, MD1, (1)Division of Research, Kaiser Permanente, Oakland, CA, (2)Kaiser Permanente San Francisco Medical Center, San Francisco, CA, (3)Kaiser Permanente Hayward Medical Center, Hayward, CA, (4)Mid-Atlantic Permanente Research Institute, Mid-Atlantic Permanente Medical Group, Rockville, MD

Disclosures:

M. Silverberg, None

L. Hurley, None

A. Prasad, None

J. Zaroff, None

D. Klein, None

M. Horberg, None

A. Go, None

J. Lo, None

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.